Evidence map›Paper›PMID 38611001›Full record

ArticleCancers2024

Clinical Validation of the Vitro HPV Screening Assay for Its Use in Primary Cervical Cancer Screening.

Beatriz Bellosillo, Raquel Ibáñez, Esther Roura, Laura Monfil, Laura Asensio-Puig, Isabel Álvarez, Mercè Muset, Yolanda Florencia, Sonia Paytubi, Álvaro de Andrés-Pablo and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Beatriz BellosilloDepartment of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
Raquel IbáñezCancer Epidemiology Research Programme, Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.
Esther RouraCancer Epidemiology Research Programme, Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.
Laura MonfilCancer Epidemiology Research Programme, Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.
Laura Asensio-PuigCancer Epidemiology Research Programme, Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.ORCID 0000-0003-1772-1923
Isabel ÁlvarezDepartment of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
Mercè MusetDepartment of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
Yolanda FlorenciaCancer Epidemiology Research Programme, Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.
Sonia PaytubiCancer Epidemiology Research Programme, Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.ORCID 0000-0002-5392-953X
Álvaro de Andrés-PabloCancer Epidemiology Research Programme, Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.ORCID 0000-0002-0432-5078
Susana CalvoDepartment of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
Laia Serrano-MunnéDepartment of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
Miguel Ángel PavónCancer Epidemiology Research Programme, Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.
Belen LloverasDepartment of Pathology, Hospital del Mar, 08003 Barcelona, Spain.
Institut d'Investigació Biomédica de Bellvitge · ESHospital Del Mar · ESUniversitat Pompeu Fabra · ES

Funding

VITRO does not apply
6 · The paper itself

Abstract

Many scientific societies have issued guidelines to introduce population-based cervical cancer screening with HPV testing. The Vitro HPV Screening assay is a fully automatic multiplex real-time PCR test targeting the L1 GP5+/GP6+ region of HPV genome. The assay detects 14 high risk (HR) HPV genotypes, identifying individual HPV16 and HPV18 genotypes, and the HPV-positive samples for the other 12 HR HPV types are subsequently genotyped with the HPV Direct Flow Chip test. Following international guidelines, the aim of this study was to validate the clinical accuracy of the Vitro HPV Screening test on ThinPrep-collected samples for its use as primary cervical cancer screening, using as comparator the validated cobas

Indexed as

cervical cancercervical screeninggenotypingHPVhuman papillomavirusvalidationVitro HPV

Identifiers

PMID38611001
PMCPMC11011158
OpenAlexW4393255523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.